Fig. 3
From: Nanomedicine for renal cell carcinoma: imaging, treatment and beyond
Fe3O4@mSiO2/PDDA/BSA-Gd2O3 nano-complex was developed as a T1-T2 dual-mode contrast agent. The combination of T1 and T2 contrast agents can integrate the high tissue resolution of T1 mode contrast imaging and the high feasibility of softer tissue detection of T2 mode contrast imaging. A Schematic illustration of the fabrication process of the nanoprobes. B T1-weighted and T2-weighted in vivo MRI images of mice post-injection of the nanocomplex at different time points (0, 15Â min, 6Â h, and 24Â h). Figure adapted from Jingjing Li et al. [80]